Focus on HIV Care

Back to articles

Virologic failure less likely with first-line efavirenz

KEY POINT

Use of efavirenz (Sustiva—Bristol-Myers Squibb) plus two nucleoside reverse-transcriptase inhibitors (NRTIs) resulted in less virologic failure compared with lopinavir/ritonavir (Kaletra—Abbott) plus two NRTIs and had similar efficacy compared with an NRTI-sparing regimen. However, virologic failure with an efavirenz-based regimen was more frequently associated with multidrug resistance than the lopinavir–ritonavir regimen.

SOURCES

Riddler SA et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095–106. 

Hirschel B et al. Initial treatment for HIV infection: an embarrassment of riches. N Engl J Med. 2008;358:2170–2.